会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • USE OF L. REUTERI FOR RECOVERY OF MICROBIOTA DYSBIOSIS IN EARLY LIFE
    • 微生物在早期生活中恢复微生物的应用
    • WO2016066763A1
    • 2016-05-06
    • PCT/EP2015/075164
    • 2015-10-29
    • NESTEC S.A.
    • GARCIA-RODENAS, Clara LuciaBERGER, BernardNGOM-BRU, CatherineLEPAGE, MelissaNEVILLE, Tara
    • A61K35/747A61K35/745A61K31/702A61P1/00A61P3/04A61P3/10
    • A61K35/747A23L33/135A23L33/40A23Y2220/71A61K31/702A61K31/733A61K35/745A61K45/06A61K2300/00
    • The invention concerns Lactobacillus reuteri for use in the prevention or treatment of microbiota dysbiosis, in particular, decreased levels of Actinobacteria and increased levels of Proteobacteria, in young mammals and in the prevention or treatment of disorders associated therewith. The microbiota dysbiosis may have been cause by numerous factors including being born by caesarean section, exposure to antibiotics in utero or after birth, or, parenteral feeding, hospitalizing, psychological stress or by gastrointestinal dysfunctions. The disorders that may be treated or prevented by preventing or treating microbiota dysbiosis include propensity to infection, allergy, type I diabetes mellitus, insulin resistance, type 2 diabetes, celiac disease, peripheral and central adiposity, obesity, necrotizing enterocolitis, inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, and functional gastrointestinal disorders such as IBS, functional diarrhea, functional constipation, recurrent abdominal pain, and dyspepsia.
    • 本发明涉及用于预防或治疗微生物群发育不良的罗拉伊氏乳杆菌(Lactobacillus reuteri),特别是在年轻哺乳动物中降低的放线菌素水平和变形杆菌水平的增加以及与之相关的病症的预防或治疗。 微生物群发育不良可能是由许多因素造成的,包括剖宫产,子宫内或出生后暴露于抗生素,肠胃外给药,住院,心理压力或胃肠功能障碍。 可能通过预防或治疗微生物群发育不良症而被治疗或预防的疾病包括感染倾向,过敏,I型糖尿病,胰岛素抵抗,2型糖尿病,腹腔疾病,外周和中枢性肥胖,肥胖,坏死性小肠结肠炎,炎性肠病, 例如克罗恩病和溃疡性结肠炎,以及功能性胃肠疾病如IBS,功能性腹泻,功能性便秘,复发性腹痛和消化不良。